Stock Financial Ratios, Dividends, Split History

CLRB / Cellectar Biosciences, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)118.24
Enterprise Value ($M)102.03
Book Value ($M)7.45
Book Value / Share0.43
Price / Book14.61
NCAV ($M)5.54
NCAV / Share0.32
Price / NCAV19.66
Share Statistics
Common Stock Shares Outstanding 16,661,446
Common Shares Outstanding 17,388,344
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.26
Return on Assets (ROA)-0.89
Return on Equity (ROE)-1.00
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio3.63
Income Statement (mra) ($M)
Revenue From Grants0.00
Operating Income-13.60
Net Income-13.56
Earnings Per Share Basic And Diluted-1.07
Cash Flow Statement (mra) ($M)
Cash From Operations-11.02
Cash from Investing-0.35
Cash from Financing-0.35
Identifiers and Descriptors
Central Index Key (CIK)1279704
Related CUSIPS

Split History

Stock splits are used by Cellectar Biosciences, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Your Daily Pharma Scoop: Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Positive

2018-07-20 seekingalpha
Discussion: Catalyst Biosciences (CBIO) announced interim data from a Phase 2/3 clinical trial of evaluating subcutaneously administered prophylactic Factor VIIa variant marzeptacog alfa (activated) in patients with hemophilia A or B with inhibitors. One administered patient showed significant improvement in prevention of bleeding in the first 96 days. Two other patients are yet to complete the first 50 days of dosing to determine any significant improvement. (82-0)

Your Daily Pharma Scoop: Voyager Advances, Roche Succeeds, Eisai Positive

2018-07-19 seekingalpha
Voyager advancing gene therapy for Parkinson's, Phase 2 data may be sufficient for U.S. marketing application (37-0)

Cellectar Biosciences Strong Preliminary Data For Rare Cancer Treatment Is Encouraging

2018-07-18 seekingalpha
Preliminary results for a phase 2 study using CLR 131 to treat one patient with Waldenstrom macroglobulinemia showed a 94% reduction in tumor burden with only 2 doses. (12-0)

Your Daily Pharma Scoop: Secondary Offering Review, Week Of June 8-15, VSTM, SRRA

2018-06-19 seekingalpha
Welcome to another week of secondary offering review. Like we have said before, secondary offerings are often a good time to enter into a stock. If a company has otherwise solid credentials but goes down on the offering, that's a good entry point, other things being constant. (87-2)

Your Daily Pharma Scoop: Aduro Biotech Moves Ahead, MannKind Up, Chimerix Dips

2018-06-11 seekingalpha
Aduro Biotech Inc. (ADRO) is a smallcap with a market capitalization of $533.397M. The company develops immunotherapy drugs, focuses on development of therapies that treat challenging diseases. The Berkeley, CA based company was founded as Oncologic, Inc. in 2000 and renamed to Aduro BioTech, Inc. in June 2008. (243-1)

CUSIP: 15117F302